Jubilant Pharmova Unit Receives Tax Order

Jubilant Generics, a subsidiary of Jubilant Pharmova, has received an income tax order for the fiscal year 2022-23, which includes tax adjustments of ₹107.89 crore. These adjustments primarily stem from transfer pricing issues.

Tax Adjustment Details

The income-tax department's order details tax adjustments totaling ₹107.89 crore for Jubilant Generics (JGL) for FY23. The core reason cited for these adjustments is the company's transfer pricing practices.

Company's Stance and Outlook

Despite the significant sum, JGL disputes the tax department's assessment. The company is preparing to file an appeal against the order. Jubilant Pharmova has indicated that it does not anticipate any material financial impact from this tax order. However, the company's filing notes a potential reduction in Deferred Tax Assets (DTA) amounting to ₹37.70 crore.

Understanding Transfer Pricing

This tax order relates to Jubilant Generics' transfer pricing arrangements for FY23. Transfer pricing involves setting prices for transactions between related entities within the same corporate group, a common area of scrutiny for tax authorities.

Next Steps in Appeal Process

Jubilant Generics will proceed with filing an appeal against the tax order. The company is also monitoring an application submitted to the Advance Pricing Authority.

Key Risks to Monitor

Investors should note the potential reduction in Deferred Tax Assets by ₹37.70 crore. The outcome of JGL's appeals and the company's success in seeking relief are also important factors.

Tracking Investor Information

For investors, key areas to track include the progress of JGL's appeal before the Commissioner of Income Tax (Appeals) and the decision from the Advance Pricing Authority.

Context Metrics

• Tax Adjustments: ₹107.89 crore (FY23)
• Potential DTA Reduction: ₹37.70 crore